ACT 256.60 Actavis Inc $ACT Hit a 52 week high of 256.80

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 10:10 AM

ACT 256.60 Actavis Inc $ACT Hit a 52 week high of 256.80 Closing the day 09:45 at 256.60 +8.66 +3.49% With a day low of 249.86 and a total volume of 1,501,240.

ACT Recent Posts: http://investorshangout.com/Actavis-Inc-ACT-53105/

ACT Actavis Inc Recent Headline News

Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - 40 mins ago
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 260.82 (+12.88), PFE: 30.40 (+0.08), TEVA: 58.20 (+0.96)

Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 1 hr 37 mins ago

AGN: 212.52 (+3.32), VRX: 141.00 (+4.27), ACT: 260.82 (+12.88)

Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 212.52 (+3.32), ACT: 260.82 (+12.88), VRX: 141.00 (+4.27), V: 251.14 (+1.34), ALXN: 191.63 (+4.85), CTSH: 53.15 (+0.09), MA: 83.46 (+0.26), ADS: 280.89 (+0.01)

Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 212.52 (+3.32), ACT: 260.84 (+12.90), AMAG: 35.73 (+0.97), BMY: 58.72 (+0.29)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST

URBN: 28.74 (-2.09), DHX: 11.48 (+0.22), ACT: 260.84 (+12.90), OME: 12.71 (-2.27), CLVS: 53.89 (+0.56), AVB: 157.85 (-0.31), PF: 32.46 (-1.26), RMTI: 10.14 (-0.44), GLW: 20.42 (+0.06), FOLD: 6.33 (-0.37)

Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.52 (+3.32), ACT: 260.84 (+12.90), VRX: 140.97 (+4.24), MRK: 59.71 (+0.25), VRX.TO: 159.43 (+5.03)

Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 212.52 (+3.32), VRX: 140.97 (+4.24), ACT: 260.85 (+12.91), SAFM: 86.62 (+1.69), PPC: 31.42 (+0.48), MIK: 22.16 (+0.51), TSN: 43.03 (unch)

Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 326.88 (+3.83), HAS: 56.16 (-0.21), ACT: 260.85 (+12.91), VRX: 140.97 (+4.24), JIVE: 6.37 (unch), FB: 74.56 (+0.32), HAL: 49.90 (+0.67), DWA: 22.59 (+0.28), AGN: 212.52 (+3.32), LNKD: 223.01 (-0.27), BHI: 66.08 (+0.85), CRM: 63.16 (+0.65)

Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 212.52 (+3.32), VRX: 140.97 (+4.24), ACT: 261.13 (+13.19), LNKD: 223.20 (-0.08), FB: 74.56 (+0.32), HAL: 49.90 (+0.67), BHI: 66.08 (+0.85), Z: 119.71 (+1.85)

Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 212.69 (+3.49), HAS: 56.16 (-0.21), AMZN: 326.88 (+3.83), VRX: 140.97 (+4.24), ACT: 261.25 (+13.31), LNKD: 223.22 (-0.06), JIVE: 6.37 (unch), FB: 74.56 (+0.32), HAL: 49.90 (+0.67), DWA: 22.59 (+0.28), CRM: 63.16 (+0.65), BHI: 66.08 (+0.85)

Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST

AGN: 212.69 (+3.49), ACT: 261.09 (+13.15), VRX: 140.97 (+4.24)

Cramer: Investors Should Ignore Analysts' Calls on Hotel, Other Stocks
at The Street - Mon Nov 17, 10:32AM CST
Analysts have been growing pessimistic on several high quality stocks and sectors. Investors should use weakness as a buying opportunity instead, Cramer said.
AGN: 212.69 (+3.49), ACT: 261.10 (+13.16), PG: 87.83 (-0.01), MAR: 76.94 (-0.23), HOT: 77.22 (+0.37)

Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - Mon Nov 17, 9:59AM CST
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 44.06 (-0.17), AGN: 212.69 (+3.49), VRX: 140.97 (+4.24), ACT: 261.10 (+13.16)

Stock Market Today: Stocks Shrug Off Japan's Recession as Deals Dominate Day
at The Street - Mon Nov 17, 9:40AM CST
U.S. stocks recover from earlier lows triggered by Japan's recession. Deals news about Baker Hughes and Allergan dominate headlines.
AGN: 212.69 (+3.49), HAS: 56.16 (-0.21), ACT: 261.14 (+13.20), HAL: 49.90 (+0.67), DWA: 22.59 (+0.28), BHI: 66.07 (+0.84)

ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Nov 17, 9:32AM CST
Rigrodsky & Long, P.A.:
AGN: 212.59 (+3.39), ACT: 261.13 (+13.19)

Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - Mon Nov 17, 9:17AM CST
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 212.68 (+3.48), VRX: 140.97 (+4.24), ACT: 260.76 (+12.82)

Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:13AM CST

ACT: 261.05 (+13.11), VRX: 140.97 (+4.24)

Valeant Comments On Allergan Announcement
PR Newswire - Mon Nov 17, 8:29AM CST
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 212.68 (+3.48), ACT: 261.05 (+13.11), VRX: 140.97 (+4.24), VRX.TO: 159.49 (+5.09)

It's official: Actavis buys Allergan
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:26AM CST

AGN: 212.68 (+3.48), ACT: 261.07 (+13.13)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ensign Lawsuit Brews: Investor Stakes High by Dec. 7

Ensign's Alleged Missteps Uncovered Man, grabbing headlines in the finance world often feels like catching a whirlwind, and yet, here we are with Ensign Group's latest debacle. This isn't some run-of-the-mill story we're sifting through. It's a class action lawsuit with teeth, aiming to rope in investors who played ball during a hefty stretch running from February 10,...

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Hims & Hers Faces Securities Lawsuit Amid Stock Dive

Hims & Hers Takes a Hit Right out of the gate, we're seeing Hims & Hers Health, Inc. (NYSE:HIMS) embroiled in a securities class action, thanks to some good old-fashioned alleged corporate shenanigans. It's one of those times where you'd cock an eyebrow and say, "What in the world were they thinking?" The FTC has slapped them with accusations of misleading privacy claims...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Master Sommeliers and Italian Producers Clash on Wine Lists

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Duolingo Faces Class Action: Deadline Looms for Plaintiffs

Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...

York Space Systems Class Action: Deadline Approaches

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...